vs
Side-by-side financial comparison of Cue Biopharma, Inc. (CUE) and INTEST CORP (INTT). Click either name above to swap in a different company.
INTEST CORP is the larger business by last-quarter revenue ($32.8M vs $21.9M, roughly 1.5× Cue Biopharma, Inc.). Cue Biopharma, Inc. runs the higher net margin — 7.2% vs 3.8%, a 3.4% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs -10.3%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs 4.9%).
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
INTTEST Corp designs, manufactures and distributes precision test and process control solutions for the global semiconductor manufacturing ecosystem. Its offerings include thermal management systems, test interface hardware, and wafer handling tools, serving semiconductor fabs, chip design firms, and automotive and industrial electronics end segments.
CUE vs INTT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.9M | $32.8M |
| Net Profit | $1.6M | $1.2M |
| Gross Margin | — | 45.4% |
| Operating Margin | 9.0% | 3.9% |
| Net Margin | 7.2% | 3.8% |
| Revenue YoY | 1292.3% | -10.3% |
| Net Profit YoY | 116.7% | -17.4% |
| EPS (diluted) | $0.05 | $0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.9M | $32.8M | ||
| Q3 25 | $2.1M | $26.2M | ||
| Q2 25 | $3.0M | $28.1M | ||
| Q1 25 | $421.0K | $26.6M | ||
| Q4 24 | $1.6M | $36.6M | ||
| Q3 24 | $3.3M | $30.3M | ||
| Q2 24 | $2.7M | $34.0M | ||
| Q1 24 | $1.7M | $29.8M |
| Q4 25 | $1.6M | $1.2M | ||
| Q3 25 | $-7.4M | $-938.0K | ||
| Q2 25 | $-8.5M | $-503.0K | ||
| Q1 25 | $-12.3M | $-2.3M | ||
| Q4 24 | — | $1.5M | ||
| Q3 24 | $-8.7M | $495.0K | ||
| Q2 24 | $-10.2M | $230.0K | ||
| Q1 24 | $-12.3M | $662.0K |
| Q4 25 | — | 45.4% | ||
| Q3 25 | — | 41.9% | ||
| Q2 25 | — | 42.6% | ||
| Q1 25 | — | 41.5% | ||
| Q4 24 | — | 39.7% | ||
| Q3 24 | — | 46.3% | ||
| Q2 24 | — | 40.6% | ||
| Q1 24 | — | 43.8% |
| Q4 25 | 9.0% | 3.9% | ||
| Q3 25 | -353.4% | -4.5% | ||
| Q2 25 | -292.3% | -3.3% | ||
| Q1 25 | -2921.4% | -10.8% | ||
| Q4 24 | — | 5.7% | ||
| Q3 24 | -264.2% | 1.6% | ||
| Q2 24 | -390.6% | 1.0% | ||
| Q1 24 | -737.8% | 1.6% |
| Q4 25 | 7.2% | 3.8% | ||
| Q3 25 | -346.6% | -3.6% | ||
| Q2 25 | -287.1% | -1.8% | ||
| Q1 25 | -2911.4% | -8.7% | ||
| Q4 24 | — | 4.1% | ||
| Q3 24 | -259.6% | 1.6% | ||
| Q2 24 | -382.7% | 0.7% | ||
| Q1 24 | -719.1% | 2.2% |
| Q4 25 | $0.05 | $0.10 | ||
| Q3 25 | $-0.07 | $-0.08 | ||
| Q2 25 | $-0.09 | $-0.04 | ||
| Q1 25 | $-0.17 | $-0.19 | ||
| Q4 24 | — | $0.13 | ||
| Q3 24 | $-0.17 | $0.04 | ||
| Q2 24 | $-0.20 | $0.02 | ||
| Q1 24 | $-0.25 | $0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.1M | $14.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.4M | $103.6M |
| Total Assets | $42.2M | $151.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.1M | $14.2M | ||
| Q3 25 | $11.7M | $16.2M | ||
| Q2 25 | $27.5M | $19.2M | ||
| Q1 25 | $13.1M | $22.0M | ||
| Q4 24 | $22.5M | $19.8M | ||
| Q3 24 | $32.4M | $18.0M | ||
| Q2 24 | $30.0M | $20.4M | ||
| Q1 24 | $41.0M | $27.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | $4.9M | ||
| Q2 25 | — | $5.9M | ||
| Q1 25 | — | $6.9M | ||
| Q4 24 | — | $7.9M | ||
| Q3 24 | $1.0M | $9.0M | ||
| Q2 24 | $2.0M | $10.0M | ||
| Q1 24 | $3.0M | $11.0M |
| Q4 25 | $26.4M | $103.6M | ||
| Q3 25 | $13.2M | $101.9M | ||
| Q2 25 | $18.2M | $102.6M | ||
| Q1 25 | $6.6M | $99.4M | ||
| Q4 24 | $17.5M | $99.8M | ||
| Q3 24 | $25.4M | $100.4M | ||
| Q2 24 | $21.6M | $99.5M | ||
| Q1 24 | $30.0M | $99.3M |
| Q4 25 | $42.2M | $151.3M | ||
| Q3 25 | $31.6M | $148.3M | ||
| Q2 25 | $40.7M | $149.7M | ||
| Q1 25 | $22.3M | $148.0M | ||
| Q4 24 | $32.2M | $152.3M | ||
| Q3 24 | $44.8M | $158.4M | ||
| Q2 24 | $42.3M | $160.6M | ||
| Q1 24 | $54.0M | $159.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.05× | ||
| Q2 25 | — | 0.06× | ||
| Q1 25 | — | 0.07× | ||
| Q4 24 | — | 0.08× | ||
| Q3 24 | 0.04× | 0.09× | ||
| Q2 24 | 0.09× | 0.10× | ||
| Q1 24 | 0.10× | 0.11× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $-1.0M |
| Free Cash FlowOCF − Capex | — | $-1.6M |
| FCF MarginFCF / Revenue | — | -4.7% |
| Capex IntensityCapex / Revenue | 0.0% | 1.6% |
| Cash ConversionOCF / Net Profit | -0.68× | -0.82× |
| TTM Free Cash FlowTrailing 4 quarters | — | $5.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.1M | $-1.0M | ||
| Q3 25 | $-9.0M | $3.5M | ||
| Q2 25 | $-3.4M | $-688.0K | ||
| Q1 25 | $-8.2M | $5.5M | ||
| Q4 24 | $-36.3M | $2.6M | ||
| Q3 24 | $-7.5M | $4.2M | ||
| Q2 24 | $-10.0M | $-5.1M | ||
| Q1 24 | $-9.8M | $2.1M |
| Q4 25 | — | $-1.6M | ||
| Q3 25 | — | $3.1M | ||
| Q2 25 | $-3.4M | $-1.1M | ||
| Q1 25 | $-8.3M | $5.3M | ||
| Q4 24 | $-36.4M | $2.4M | ||
| Q3 24 | $-7.5M | $3.7M | ||
| Q2 24 | $-10.0M | $-5.4M | ||
| Q1 24 | $-9.8M | $1.7M |
| Q4 25 | — | -4.7% | ||
| Q3 25 | — | 11.8% | ||
| Q2 25 | -116.5% | -4.1% | ||
| Q1 25 | -1976.7% | 19.9% | ||
| Q4 24 | -2309.3% | 6.6% | ||
| Q3 24 | -225.7% | 12.4% | ||
| Q2 24 | -376.2% | -15.9% | ||
| Q1 24 | -573.0% | 5.8% |
| Q4 25 | 0.0% | 1.6% | ||
| Q3 25 | 0.0% | 1.6% | ||
| Q2 25 | 0.9% | 1.6% | ||
| Q1 25 | 35.6% | 0.9% | ||
| Q4 24 | 4.2% | 0.4% | ||
| Q3 24 | 0.0% | 1.7% | ||
| Q2 24 | 0.4% | 0.9% | ||
| Q1 24 | 3.2% | 1.1% |
| Q4 25 | -0.68× | -0.82× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.72× | ||
| Q3 24 | — | 8.58× | ||
| Q2 24 | — | -22.13× | ||
| Q1 24 | — | 3.13× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
INTT
| Environmental Technologies | $8.3M | 25% |
| Semiconductor Market | $6.9M | 21% |
| Thermal Testing Products | $6.4M | 19% |
| Service And Other Products | $4.8M | 15% |
| Oem Integrators And Distributor | $3.5M | 11% |
| Semiconductor Production Test Products | $3.0M | 9% |
